Thomas Pilgrim

Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture

Brinkmann C, Abdel-Wahab M, Bedogni F, Bhadra O, Charbonnier G, Conradi L, Hildick-Smith D, Kargoli F, Latib A, Van Mieghem N, Mylotte D, Landes U, Pilgrim T, Stripling J, Taramasso M, Tchétché D, Testa L, Thiele H, Webb J, Windecker S, Witt J, Wohlmuth P, Schofer J

November 19, 2021 | 10.4244/EIJ-D-21-00254

Transcatheter paravalvular leak closure: catch me if you can

Pilgrim T, Okuno T

October 20, 2021 | 10.4244/EIJV17I9A121

Coronary interventions

Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition

Gragnano F, Spirito A, Corpataux N, Vaisnora L, Galea R, Gargiulo G, Siontis G, Praz F, Lanz J, Billinger M, Hunziker L, Stortecky S, Pilgrim T, Bär S, Ueki Y, Capodanno D, Urban P, Pocock S, Mehran R, Heg D, Windecker S, Räber L, Valgimigli M

June 8, 2021 | 10.4244/EIJ-D-21-00181

Interventions for valvular disease

Outcomes of Valve-in-Valve Transcatheter Aortic Valve Implantation with and without Bioprosthetic Valve Fracture

Brinkmann C, Abdel-Wahab M, Bedogni F, Bhadra OD, Charbonnier G, Conradi L, Hildick-Smith D, Kargoli F, Latib A, Van Mieghem N, Mylotte D, Landes U, Pilgrim T, Stripling J, Taramasso M, Tchétché D, Testa L, Thiele H, Webb J, Windecker S, Witt J, Wohlmuth P, Schofer J

May 25, 2021 | 10.4244/EIJ-D-21-00254

Coronary interventions

Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores

Ueki Y, Bär S, Losdat S, Otsuka T, Zanchin C, Zanchin T, Gragnano F, Gargiulo G, Siontis G, Praz F, Lanz J, Hunziker L, Stortecky S, Pilgrim T, Heg D, Valgimigli M, Windecker S, Räber L

August 28, 2020 | 10.4244/EIJ-D-20-00052

Interventions for valvular disease

Feasibility and safety of transcaval transcatheter aortic valve implantation: a multicentre European registry

Costa G, De Backer O, Pilgrim T, Kasel M, Redwood S, Aminian A, Lanz J, Michel J, Patterson T, Windecker S, Prendergast B, Greenbaum A, Søndergaard L

February 7, 2020 | 10.4244/EIJ-D-19-00797

Optimal fluoroscopic viewing angles of right-sided heart structures in patients with tricuspid regurgitation based on multislice computed tomography

Xiong T, Pighi M, Thériault-Lauzier P, Leipsic J, Spaziano M, Martucci G, Buithieu J, Mousavi N, Pilgrim T, Praz F, Windecker S, Chen M, Piazza N

November 15, 2019 | 10.4244/EIJ-D-19-00618

Interventions for valvular disease

Bioprosthetic Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA) during transcatheter aortic valve-in-valve implantation with bioprosthetic valve fracturing via the transcaval access

Lanz J, Pilgrim T, Greenbaum A, Windecker S

October 19, 2018 | 10.4244/EIJ-D-18-00553

Current state of alternative access for transcatheter aortic valve implantation

Lanz J, Greenbaum A, Pilgrim T, Tarantini G, Windecker S

September 7, 2018 | 10.4244/EIJ-D-18-00552

A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial

Iglesias JF, Mueller O, Zaugg S, Roffi M, Kurz D, Vuilliomenet A, Weilenmann D, Kaiser C, Tapponnier M, Heg D, Valgimigli M, Eeckhout E, Jüni P, Windecker S, Pilgrim T

August 24, 2018 | 10.4244/EIJ-D-17-00734

Interventions for valvular disease

Prognostic impact of invasive haemodynamic measurements in combination with clinical and echocardiographic characteristics on two-year clinical outcomes of patients undergoing transcatheter aortic valve implantation

Franzone A, O’Sullivan C, Stortecky S, Heg D, Lanz J, Vollenbroich R, Praz F, Piccolo R, Asami M, Roost E, Räber L, Valgimigli M, Windecker S, Pilgrim T

April 7, 2017 | 10.4244/EIJ-D-16-00790

Coronary interventions

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction

Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Mueller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab A, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, Jüni P, Windecker S

December 9, 2016 | 10.4244/EIJY15M12_09

Coronary interventions

External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre investigation

Spitzer E, Hadorn S, Zanchin T, Yamaji K, Moschovitis A, Pilgrim T, Stortecky S, Jüni P, Heg D, Windecker S, Räber L

October 20, 2016 | 10.4244/EIJV12I9A185

Interventions for valvular disease

Bilateral, reversible coronary obstruction during aortic valve-in-valve implantation of a repositionable valve system

Praz F, Moschovitis A, Stortecky S, Pilgrim T, Eberle B, Windecker S

October 20, 2016 | 10.4244/EIJV12I9A194

Coronary interventions

Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial

Franzone A, Taniwaki M, Rigamonti F, Heg D, Piccolo R, Roffi M, Tüller D, Mueller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Jüni P, Windecker S, Pilgrim T

August 5, 2016 | 10.4244/EIJV12I5A99

Interventions for valvular disease

Effect of resting heart rate on two-year clinical outcomes of high-risk patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation

O’Sullivan C, Spitzer E, Heg D, Praz F, Stortecky S, Huber C, Carrel T, Pilgrim T, Windecker S

July 20, 2016 | 10.4244/EIJV12I4A83

Coronary interventions

Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study

Räber L, Onuma Y, Brugaletta S, Garcia-Garcia H, Backx B, Iñiguez A, Okkels Jensen L, Cequier-Fillat A, Pilgrim T, Christiansen E, Hofma S, Suttorp M, Serruys P, Sabaté M, Windecker S

July 20, 2016 | 10.4244/EIJY15M08_03

Will this trial change my practice? ABSORB II trial (a bioresorbable vascular scaffold versus drug-eluting stent in coronary disease)

De Palma R, Byrne R, van Geuns R, Pilgrim T, Jüni P, Al Rashdan I

July 20, 2015 | 10.4244/EIJV11I3A72

Five-year results of a randomised comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularisation

Pilgrim T, Räber L, Limacher A, Wenaweser P, Cook S, Stauffer J-C, Garachemani A, Moschovitis A, Meier B, Jüni P, Windecker S

March 20, 2015 | 10.4244/EIJY15M01_04

Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents

O’Sullivan C, Stefanini G, Räber L, Heg D, Taniwaki M, Kalesan B, Pilgrim T, Zanchin T, Moschovitis A, Büllesfeld L, Khattab A, Meier B, Wenaweser P, Jüni P, Windecker S

January 20, 2014 | 10.4244/EIJV9I9A182

Thomas Pilgrim

Latest news